SoloPak Laboratories, Inc.; Withdrawal of Approval of 1 New Drug Application and 38 Abbreviated New Drug Applications

الملخص

The Food and Drug Administration (FDA) is withdrawing approval of 1 new drug application (NDA) and 38 abbreviated new drug applications (ANDA's). SoloPak Laboratories, Inc., notified the agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.